GAUDIUMIVFGaudium IVF and Women Health Limited
Healthcare · Medical Care Facilities · NSE · as of 2026-11-03 (delayed ~30 min in market hours)
Gaudium IVF and Women Health Limited provides in vitro fertilization (IVF) treatment in India. The company offers fertility and reproductive health services, including intracytoplasmic sperm injection (ICSI), intrauterine insemination (IUI), and ovulation induction; polycystic ovarian syndrome (PCOS)/ polycystic ovarian disease (PCOD); endometriosis treatment; ovulation induction; and laser assisted embryo implantation services. It also provides male infertility treatment services; egg freezing; embryo freezing; frozen embryo transfer; gynae consultation; laparoscopy for infertility; diagnostic services; and support and counselling services. In addition, the company operates hospital, in-house pharmacy; and 7 hubs (IVF centers) and 28 spokes. The company was founded in 2009 and is based in New Delhi, India.
Price & Volume
Loading chart…
Key Ratios
“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.
Active Pattern Signals
None of the 16 pattern scanners currently detects a setup on GAUDIUMIVF — signals appear here automatically when one forms (checked on every data refresh). The Trade Plan on the right always provides stop-loss and target levels regardless.
Why avoid
- • Risk gate: safety score is only 30/100 — volatility, drawdown or liquidity is too poor for a buy call, whatever the chart says
- • Profit growth: -50.0% YoY
- • Dividend yield: 0.00%
- • Price vs SMA50: below
- • Volume: 0.1x 20-day average
Bull case
- • ROE: 16.1%
- • ROCE: 20.1%
- • Debt/Equity: 0.16
- • MACD: fresh bullish crossover
Bear case
- • Profit growth: -50.0% YoY
- • Dividend yield: 0.00%
- • Price vs SMA50: below
- • Volume: 0.1x 20-day average
Key risks
- • Elevated volatility / drawdown profile — size positions accordingly
- • Momentum is fading versus the broader market
- • Profit growth: -50.0% YoY
- • Dividend yield: 0.00%
Algorithmic analysis for research only — not SEBI-registered investment advice.
Trade Plan
Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹6.20). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.